Company

Ahead Together

We unite science, technology and talent to get ahead of disease together.

Close Video

Scroll to explore

Ahead Together

Getting ahead of disease is one of the most inspiring challenges there is on the planet.

Explore how we will positively impact the health of 2.5 billion people over the next 10 years

Purpose, strategy and culture

GSK Pakistan at a glance

GETTING AHEAD OF DISEASE IN

80+

markets

Careers

INNOVATION

global R&D centres

Global R&D

PIPELINE

60+

vaccines and medicines in development

Innovation

TRUST

1st

in the Access to Medicine Index for people in low- to middle-income countries

Responsibility

PERFORMANCE

£29.3bn

turnover in 2022

Global Investors

Our leadership team

Find out more about our board and global leadership team who have overall responsibility for delivering our ambition, strategy and culture.

Board of directors and leadership team

GlaxoSmithKline Pakistan Limited

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. In Pakistan, the Company has been providing trusted quality medicines, and vaccines to more than 200 million patients for over seven decades.

Our culture of being ambitious for patients, accountable for impact, and doing the right thing are the foundations for how, together, we’ll deliver for our patients and shareholders, making GSK a company where people can thrive. To achieve this, GSK has built an extensive manufacturing and distribution network, committed to growth and delivering a step change in performance.

GSK Pakistan caters to many therapy areas which include Anti-infectives, Dermatology, Analgesics, and Vaccines. We aim to consistently produce and improve access to quality medicines to make a positive impact on patients’ lives. Our key pharmaceutical brands include Augmentin, Velosef, Amoxil, Dermovate, Clobevate, Betnovate, and Calpol.

GSK holds the position of the largest multinational pharmaceutical company in Pakistan, based on volume, value, and the number of prescriptions generated*. Additionally, among the 700+* pharmaceutical companies operating in the country, both local and multinational, GSK ranks within the top 3 in terms of value and leads in volume. We employ around 1,700 people across our manufacturing, and commercial functions. Our Global Supply Chain (GSC) division, which manufactures over 430 million packs annually, consists of three facilities, all of which are situated in Karachi at F-268 SITE, West Wharf, and Korangi.

GSK F-268 is Pakistan’s largest manufacturing facility situated in Sindh Industrial Trading Estate (SITE), Karachi. This site produces 215 million packs each year from 3 value streams, namely Liquids, Penicillin, and Tablets. Some of the leading brands produced at this site include Augmentin, Amoxil, and Calpol.

This site is in the vicinity of Karachi Port, mainly manufacturing Dermatology products, including ointments, creams, and lotions. In addition, the site is responsible for manufacturing Otics (ear drops) and Spansules. Well-known products manufactured at West Wharf include Betnovate, Dermovate and Polyfax. The site manufactures over 174 million packs annually.

Policy positions

We have policies in place across GSK to ensure we meet the high standards we set ourselves as a company, and those that are expected of us externally.

Our Code (PDF - 2.4MB)

The Anti-Bribery and Corruption (ABAC) Programme is part of GSK’s response to the threat and risk of bribery and corruption. The programme includes an ABAC Policy and Standard, which have been designed to help staff and external parties understand bribery and corruption risk, and their responsibilities to actively combat it.

Anti Bribery and Corruption Policy (PDF - 330.5KB)

Our Third Party Oversight Programme helps control risks from third party business engagements with suppliers, distributors and other business partners. We want to work with business partners who share our commitment of high ethical standards and operating in a responsible way.

Working with Third Parties (PDF - 252.4KB)

Promotion and Scientific Engagement (PDF - 214.0KB)

GSK is committed to protecting people and the environment, moving towards our sustainability ambitions and promoting wellbeing and the safety of our people. Our Environment, Health and Safety policy sets out our approach to managing EHSS risks and creating opportunities across our organisation to fulfil our EHSS protection commitments, both internally and externally.

EHSS Policy GSK Pakistan 2021 (PDF - 443.5KB)

To demonstrate leadership and commitment to establish a framework for making Quality Management System integral to the management of GSK business.

GSK Quality Policy (PDF - 105.4KB)

Visit our global site for a complete list of global policies

Global Therapeutic areas

Infectious diseases

For over 70 years we have been pioneering research methods to help protect people from infections.

HIV

Our work in HIV is carried out entirely through ViiV Healthcare, which GSK majority owns with Pfizer

Oncology

Our expertise in oncology allows us to bring groundbreaking cancer therapies to our patients.

Immunology

We’re focused on unlocking the science of the immune system to understand how the body’s react.

Opportunity-driven

Our current opportunity-driven ares of focus.

GSK on social

As industry leaders in applying functional genomics to improve medicine discovery & development, we welcome @GOVUK's Genome Implementation Plan. As genomics continues to revolutionise science, we can continue to help find better medicines, faster! gsk.to/3f0KKAT

Twitter @GSK
“The best advice was from my Dad.” Sumitra, Vaccines, Singapore, tells us about unexpected journeys and why she’s proud of our industry’s response to Covid-19. She’s one of our #OutstandingPeople delivering world-class science & Innovation #ItsInOurGenes gsk.to/3fxIhN4

Twitter @GSK
Tomorrow we bring together NGOs, government and policymakers @devex #WHA74 to discuss why investing in community health workers is so critical. Fiona Smith-Laittan, VP Global Health, will share how we've helped train 30,000 through our partnership with @savetheChildrenUK. twitter.com/devex/status/1…

Twitter @GSK
#News for #investors and #media: Canadian biopharma @medicagoinc have announced positive interim Phase 2 results for the adjuvanted #COVID19 #vaccine candidate, which combines their innovative plant-based vaccine technology with our pandemic adjuvant. gsk.to/3eSqZeC

Twitter @GSK
What’s next for real-world evidence? Real-world studies are already helping to shape the future of evidence-based medicine, generating important data on how our medicines benefit patients. #ATS2021 gsk.to/3ygw4VG

Twitter @GSK
At GSK we have a 50-year legacy of delivering practice-changing breakthroughs in respiratory care. We’re proud to share our research at #ATS2021 as we continue to expand our knowledge of respiratory conditions and pursue innovative solutions for those struggling to breathe.

Twitter @GSK
Today we’re marking #IDAHOBIT2021 and standing strong with our #LGBT colleagues in support of equality. At GSK, we’re committed to an inclusive workplace where all employees feel a sense of belonging and can be their authentic selves. 🌈 Learn more:gsk.to/2SRqMQdV9

Twitter @GSK
Vaccines have already been helping protect people from diseases for well over 100 years, and at GSK we're exploring the potential of mRNA to create next-generation vaccines. Go #BehindTheScience to learn more 👇gsk.com/en-gb/behind-t…G

Twitter @GSK
DYK As well as providing our adjuvant technology to several organisations working on promising #COVID19 vaccines, we’re collaborating with partners to find other ways to tackle the pandemic, including exploring potential therapeutic or treatment options: gsk.to/3onGWN9

Twitter @GSK
#News for #investors and #media: Today, we’ve announced positive Phase 2 results for the adjuvanted #COVID19 vaccine candidate we’re co-developing with @sanofi. A Phase 3 study is expected to begin in the coming weeks. Learn more: gsk.to/3byWmsG

Twitter @GSK